Design of Antibacterial Agents

Molecular Medical Microbiology

Volumn , Issue , 2014, Pages 611-626

  Basarab, Gregory S ^a   Eakin, Ann E ^a   Nichols, Wright W ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Antibiotic discovery; Chemistry; Design; DNA gyrase; Drug development; Drug discovery; Topoisomerase

Indexed keywords

EID: 84961175033     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-397169-2.00034-2     Document Type: Chapter

References (106)

1. M. Segall Why is it still drug discovery? Eur Biopharm Rev 2008 Spring Issue.
2. A.P. Beresford., H.E. Selick., M.H. Tarbit The emerging importance of predictive ADME simulation in drug discovery Drug Discov Today 7 2002 109-116.
3. A. Wlodawer., J.W. Erickson Structure-based inhibitors of HIV-1 protease Ann Rev Biochem 62 1993 543-585.
4. D.L. Kempf Design of symmetry based, peptidomimetic inhibitors of human immunodeficiency virus protease Methods Enzymol 241 1994 334-354.
5. J.P. Vacca Design of tight binding human immunodeficiency virus type I protease inhibitors Methods Enzymol 241 1994 311-334.
6. K.R. Romines., R.A. Chrusciel 4-Hydroxypyrones and related templates as nonpeptidic protease inhibitors Curr Med Chem 2 1995 825-838.
7. G.V. De Lucca., S. Erickson-Viitanen., P.Y.S. Lam Cyclic HIV protease inhibitors capable of displacing the active site structural water molecule Drug Discov Today 2 1997 6-18.
8. M.J. Macielag Chemical properties of antimicrobials and their uniqueness T.J. Dougherty., M.J. Pucci Antibiotic Discovery and Development 2012 Springer New York 793-820.
9. L.L. Silver Rational approaches to antibacterial discovery; pre-genomic directed and phenotypic screening T.J. Dougherty., M.J. Pucci Antibiotic Discovery and Development 2012 Springer New York 33-78.
10. S.B. Singh Natural products in the 21st century T.J. Dougherty., M.J. Pucci Antibiotic Discovery and Development 2012 Springer New York 821-847.
11. G.N. Rolinson β-Lactam antibiotics J Antimicrob Chemother 17 1985 5-36.
12. M.G.P. Page Beta-lactam antibiotics T.J. Dougherty., M.J. Pucci Antibiotic Discovery and Development 2012 Springer New York 79-118.
13. I. Phillips., K.P. Shannon Aminoglycosides and aminocyclitols F. O’Grady., H.P. Lambert. R.G. Finch., D. Greenwood Antibiotic and Chemotherapy 7th ed. 1997 Churchill Livingstone Edinburgh 164-201.
14. E.S. Armstrong., C.F. Kostrub., R.T. Cass., H.E. Moser., A.W. Serio., G.H. Miller Aminoglycosides T.J. Dougherty., M.J. Pucci Antibiotic Discovery and Development 2012 Springer New York 229-270.
15. D. Felmingham Glycopeptides F. O’Grady., H.P. Lambert. R.G. Finch., D. Greenwood Antibiotic and Chemotherapy 7th ed. 1997 Churchill Livingstone Edinburgh 363-368.
16. D.J. Payne., M.N. Gwynn., D.J. Holmes., D.L. Pompliano Drugs for bad bugs: confronting the challenges of antibacterial discovery Nat Rev Drug Discov 6 2007 29-40.
17. A.P. Tomaras., J.L. Crandon., C.J. McPherson., M.A. Banevicius., S.M. Finegan., R.L. Irvine., et al. Adaptation-based resistance to siderophore-conjugated antibacterial agents by Pseudomonas aeruginosa Antimicrob Agents Chemother 57 2013 4197-4207.
18. D.A. Rasko., V. Sperandio Anti-virulence strategies to combat bacteria-mediated disease Nat Rev Drug Discov 9 2010 117-128.
19. R.L. Then., H.G. Sahl Anti-infective strategies of the future: is there room for species-specific antibacterial agents? Curr Pharm Des 16 2010 555-566.
20. D. Amsterdam Susceptibility testing of antimicrobials in liquid media V. Lorian. Antibiotics in Laboratory Medicine 5th ed. 2005 Williams & Wilkins Baltimore 61-143.
21. G.A. Pankey., L.D. Sabath Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections Clin Infect Dis 38 2004 864-870.
22. Finberg RW, Moellering RC, Tally FP, Craig WA, Pankey GA, Dellinger EP, et al. The importance of bactericidal drugs: future directions in infectious disease. Clin Infect Dis 2004;39:1314-20.
23. S.M. McLeod., T.J. Dougherty., M.J. Pucci Novel antibacterial targets/identification of new targets by comparative genomics T.J. Dougherty., M.J. Pucci Antibiotic Discovery and Development 2012 Springer New York 881-900.
24. A. Luttinger The twisted ‘life’ of DNA in the cell: bacterial topoisomerases Mol Microbiol 15 1995 601-606.
25. M. Hensel., J.E. Shea., C. Gleeson., M.D. Jones., E. Dalton., D.W. Holden Simultaneous identification of bacterial virulence genes by negative selection Science 269 1995 400-403.
26. M. Prax., C.Y. Lee., R. Bertram An update on the molecular genetics toolbox for staphylococci Microbiology 159 2013 421-435.
27. C. Baldock., G.-J. de Boer., J.B. Rafferty., A.R. Stuitje., D.W. Rice The mechanism of action of the diazaborines Biochem Pharmacol 55 1998 1541-1549.
28. D.H. Williams., J.P. Waltho Molecular basis of the activity of antibiotics of the vancomycin group Biochem Pharmacol 17 1988 133-141.
29. R.D. Fleischmann., M.D. Adams., O. White., R.A. Clayton., E.F. Kirkness., et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd Science 269 1995 496-512.
30. F.R. Blattner., G. Plunkett., C.A. Bloch., N.T. Perna., V. Burland., M. Riley., et al. The complete genome sequence of Escherichia coli K-12 Science 277 1997 1453-1462.
31. D.T.W. Chu., J.J. Plattner., L. Katz New directions in antibacterial research J Med Chem 39 1997 3853-3874.
32. D.J.C. Knowles., N. Foloppe., N.B. Matassova., A.I.H. Murchie The bacterial ribosome, a promising focus for structure-based drug design Curr Opin Pharmacol 2 2002 501-506.
33. A.E. Allsop Bacterial genome sequencing and drug discovery Curr Opin Biotechnol 9 1998 637-642.
34. D.T. Moir., K.J. Shaw., R.S. Hare., G.F. Vovis Genomics and antimicrobial drug discovery Antimicrob Agents Chemother 43 1999 439-446.
35. K. Duncan., J. van Heijenoort., C.T. Walsh Purification and characterisation of the d-alanyl-d-alanine adding enzyme from Escherichia coli Biochemistry 29 1990 2379-2386.
36. S.M. Hammond., A. Claesson., A.M. Jansson., L.-G. Larsson., B.G. Pring., C.M. Town., et al. A new class of synthetic antibacterials acting on lipopolysaccharide biosynthesis Nature 327 1987 730-732.
37. H.R. Onishi., B.A. Pelak., L.S. Gerckens., L.L. Silver., F.M. Kahan., M.-H. Vhen., et al. Antibacterial agents that inhibit lipid A biosynthesis Science 274 1996 980-982.
38. P. Canepari., M. Boaretti., M. Del Mar Lleo., G. Satta Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin, LY-146032 Antimicrob Agents Chemother 34 1990 1220-1226.
39. C.W. Ford., J.C. Hamel., D. Stapert., J.K. Moerman., D.K. Hutchinson., M.R. Barbachyn., et al. Oxazolidinones: new antibacterial agents Trends Microbiol 5 1997 196-200.
40. Barbachyn MR. Oxazolidinone antibacterial agents. In: Dougherty TJ, Pucci MJ, editors. Antibiotic Discovery and Development. New York: Springer; 2012. p. 271-300.
41. C.B. Inderlied Antimycobacterial agents: in vitro susceptibility testing, spectrums of activity, mechanisms of action and resistance, and assays for activity in biological fluids V. Lorian. Antibiotics in Laboratory Medicine 3rd ed. 1991 Williams & Wilkins Baltimore 134-197.
42. R.J. Olsen., S.W. Long., J.M. Musser Bacterial genomics in infectious disease and the clinical pathology laboratory Arch Pathol Lab Med 136 2012 1414-1422.
43. V. Kisand., T. Lettieri Genome sequencing of bacteria: sequencing, de novo assembly and rapid analysis using open source tools BMC Genomics 14 2013 211-221.
44. J.G. Swoboda., J. Campbell., T.C. Meredith., S. Walker Wall teichoic acid function, biosynthesis, and inhibition ChemBioChem 11 2010 35-45.
45. D.-J. Scheffers., M.G. Pinho Bacterial cell wall synthesis: new insights from localization studies Microbiol Mol Biol Rev 69 2005 585-607.
46. H. Nikaido Antibiotic resistance caused by Gram-negative multidrug efflux pumps Clin Infect Dis 27 1998 S32-S41.
47. S. Murakami Multidrug efflux transporter, AcrB-the pumping mechanism Curr Opin Struct Biol 18 2008 459-465.
48. I.T. Paulsen., M.H. Brown., R.A. Skurray Proton-dependent multidrug efflux systems Microbiol Rev 60 1996 575-608.
49. H. Nikaido., D.G. Thanassi Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples Antimicrob Agents Chemother 37 1993 1393-1399.
50. W.W. Nichols Permeability of bacteria to antibacterial agents T.J. Dougherty., M.J. Pucci Antibiotic Discovery and Development 2012 Springer New York 849-879.
51. J.I. Manchester., E.T. Buurman., G.S. Bisacchi., R.E. McLaughlin Molecular determinants of AcrB-Mediated bacterial efflux implications for drug discovery J Med Chem 55 2012 2532-2537.
52. M.H. Miller Aminoglycoside transport N.H. Georgopapadakou. Drug Transport in Antimicrobial and Anticancer Chemotherapy 1995 Marcel Dekker New York 175-219.
53. H.W. Taber., J.P. Mueller., P.F. Miller., A.S. Arrow Bacterial uptake of aminoglycoside antibiotics Microbiol Rev 51 1987 439-457.
54. A. Bauernfeind., N.H. Georgopapadakou Clinical significance of antibacterial transport N.H. Georgopapadakou. Drug Transport in Antimicrobial and Anticancer Chemotherapy 1995 Marcel Dekker New York 1-19.
55. T. Mazzei., E. Mini., A. Novelli., P. Periti Chemistry and mode of action of macrolides J Antimicrob Chemother 31 Suppl. C 1993 1-9.
56. H. Nikaido., M. Vaara Molecular basis of bacterial outer membrane permeability Microbiol Rev 49 1985 1-32.
57. S. Murakami., R. Nakashima., E. Yamashita., T. Matsumoto., A. Yamaguchi Crystal structures of a multidrug transporter reveal a functionally rotating mechanism Nature 443 2006 173-179.
58. L. Fernández., R.E.W. Hancock Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance Clin Microbiol Rev 26 2012 661-681.
59. T. Velkov., P.E. Thompson., R.L. Nation., J. Li Structure-activity relationships of polymyxin antibiotics J Med Chem 53 2010 1898-1916.
60. C. Vilhena., A. Bettencourt Daptomycin: a review of properties, clinical use, drug delivery and resistance Mini Rev Med Chem 12 2012 202-209.
61. Yu NY, Wagner JR, Laird MR, Melli G, Rey S, Lo R, et al. PSORTb 3.0: improved protein subcellular localization prediction with refined localization subcategories and predictive capabilities for all prokaryotes. Bioinformatics; 2010;26:1608-15.
62. M.H. Block., W.W. Nichols Design of antibacterial agents M. Sussman. Molecular Medical Microbiology vol 1 2001 Academic Press London 609-626.
63. C.A. Lipinski., F. Lombardo., B.W. Dominy., P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv Drug Deliv Rev 23 1997 3-25.
64. J. Zhu., J. Wang., H. Yu., Y. Li., T. Hou Recent developments of in silico predictions of oral bioavailability Comb Chem High Throughput Screen 14 2011 362-374.
65. J.B. Taylor., P.D. Kennewell Modern Medicinal Chemistry 1993 Ellis Horwood Chichester, UK.
66. L. Di., E.H. Kerns., G.T. Carter Drug-like property concepts in pharmaceutical design Curr Pharm Des 18 2009 2184-2194.
67. K. Luthman., B. Steffansen Chemical approaches to improving bioavailability properties of oral drug candidates B. Steffensen., B. Brodin. C.U. Nielsen Molecular Biopharmaceutics 2010 Pharmaceutical Press London 71-100.
68. R. O’Shea., H.E. Moser Physiochemical properties of antibacterial compounds: implications for drug discovery J Med Chem 51 2008 2871-2878.
69. A.A. Miller., G.L. Bundy., J.E. Mott., J.E. Skepner., T.P. Boyle., D.W. Harris., et al. Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors Antimicrob Agents Chemother 52 2008 2806-2812.
70. S. Ricciardi., S. Tornao., F. de Marinis Toxicity of targeted therapy in non-small-cell lung cancer management Clin Lung Cancer 10 2009 28-35.
71. B.J. Druker., N.B. Lydon Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia J Clin Invest 105 2000 3-7.
72. R.J. Motzer., T.E. Hutson., P. Tomczak., M.D. Michaelson., R.M. Bukowski., O. Rixe., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115-124.
73. L.F. Kuyper., B. Roth., D.P. Baccanari., R. Ferone., C.R. Beddell., J.N. Champness., et al. Receptor based design of dihydrofolate reductase inhibitors: comparison of crystallographically determined enzyme binding with enzyme affinity in a series of carboxy-substituted trimethoprim derivatives J Med Chem 28 1985 303-311.
74. G. Martinez-Botella., J.N. Breen., J.E.S. Duffy., J. Dumas., B. Geng., I.K. Gowers., et al. Discovery of selective and potent inhibitors of gram-positive bacterial thymidylate kinase (TMK) J Med Chem 55 2012 10010-10021.
75. M.F. Brown., U. Reilly., J.A. Abramite., J.T. Arcari., R. Oliver., R.A. Barham., et al. Potent inhibitors of LpxC for the treatment of gram-negative infections J Med Chem 55 2012 914-923.
76. +-dependent DNA ligase inhibitors with broad-spectrum activity and antibacterial efficacy in vivo Antimicrob Agents Chemother 55 2011 1088-1096.
77. J.F. Axten., J.R. Medina., C.W. Blackledge., C. Duquenne., S.W. Grant., M.A. Bobko., et al. Acylprolinamides: A new class of peptide deformylase inhibitors with in vivo antibacterial activity Bioorg Med Chem Lett 22 2012 4028-4032.
78. G.S. Basarab., J.I. Manchester., S. Bist., P.A. Boriack-Sjodin., B. Dangel., R. Illingworth., et al. Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents J Med Chem 56 2013 8712-8735.
79. L.C. Axford., P.K. Agarwal., K.H. Anderson., L.N. Andrau., J. Atherall., S. Barker., et al. Design, synthesis and biological evaluation of α-substituted isonipecotic acid benzothiazole analogues as potent bacterial type II topoisomerase inhibitors Bioorg Med Chem Lett 23 2013 6598-6603.
80. M. Uria-Nickelsen., G. Neckermann., S. Sriram., B. Andrews., J.I. Manchester., D. Carcanague., et al. Novel topoisomerase inhibitors: microbiological characterisation and in vivo efficacy of pyrimidines Int J Antimicrob Agents 22 2013 5150-5156.
81. M. Trzoss., D.C. Bensen., X. Li., Z. Chen., T. Lam., J. Zhang., et al. Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: development of inhibitors with broad spectrum, gram-negative antibacterial activity Bioorg Med Chem Lett 23 2013 1537-1543.
82. J.I. Manchester., D.D. Dussault., J.A. Rose., P.A. Boriack-Sjodin., M. Uria-Nickelsen., G. Ioannidis., et al. Discovery of a novel azaindole class of antibacterial agents targeting the ATPase domains of DNA gyrase and topoisomerase IV Bioorg Med Chem Lett 22 2012 5150-5156.
83. S.M. Ronkin., M. Badia., S. Bellon., A. Grillot., C.H. Gross., T.H. Grossman., et al. Discovery of pyrazolthiazoles as novel and potent inhibitors of bacterial gyrase Bioorg Med Chem Lett 20 2010 2828-2831.
84. J.T. Starr., R.J. Sciotti., D.L. Hanna., M.D. Huband., L.M. Mullins., H. Cai., et al. 5-(2-Pyrimidinyl)-imidazo[1, 2-a]pyridines are antibacterial agents targeting the ATPase domains of DNA gyrase and topoisomerase IV Bioorg Med Chem Lett 19 2009 5302-5306.
85. S.P. East., C.B. White., O. Barker., S. Barker., J. Bennett., D. Brown., et al. DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: synthesis and antibacterial activity Bioorg Med Chem Lett 19 2009 894-899.
86. T.H. Grossman., D.J. Bartels., S. Mullin., C.H. Gross., J.D. Parsons., Y. Liao., et al. Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds Antimicrob Agents Chemother 51 2007 657-666.
87. D.B. Wigley., G.J. Davies., E.J. Dodson., A. Maxwell., G. Dodson Crystal structure of the N terminal fragment of the DNA gyrase B protein Nature 351 1991 624-629.
88. R.J. Lewis., O.M.P. Singh., C.V. Smith., A. Maxwell., T. Skarzynski., A.J. Wonacott., et al. Crystallisation of inhibitor complexes of an N-terminal 24-kDa fragment of the DNA gyrase B protein J Mol Biol 241 1994 128-130.
89. R.J. Lewis., O.M.P. Singh., C.V. Smith., T. Skarzynski., A. Maxwell., A.J. Wonacott., et al. The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X-ray crystallography EMBO J 15 1996 1412-1420.
90. F.T.F. Tsai., O.M.P. Singh., T. Skarzynski., A.J. Wonacott., S. Weston., A. Tucker., et al. The high resolution crystal structure of a 24-kDa gyrase B fragment from Escherichia coli complexed with one of the most potent coumarin inhibitors, clorobiocin Proteins: Struct, Funct, Genet 28 1997 41-52.
91. I. Laponogov., M.K. Sohi., D.A. Veselkov., X.-A. Pan., R. Sawhney., A.W. Thompson., et al. Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases Nat Struct Mol Biol 16 2009 667-669.
92. C. Fan., P.C. Moews., C.T. Walsh., J.R. Knox Vancomycin resistance: structure of d-alanine:d-alanine ligase at 2.3 Å resolution Science 266 1994 439-443.
93. C. Baldock., J.B. Rafferty., S.E. Sedelnikova., P.J. Baker., A.R. Stuitje., A.R. Slabas., et al. A mechanism of drug action revealed by structural studies of enoyl reductase Science 274 1996 2107-2110.
94. C.E. Levy., A. Roujeinikova., S. Sedelnikova., P.J. Baker., A.R. Stuitje., A.R. Slabas., et al. Molecular basis of triclosan activity Nature 398 1999 383-384.
95. A. Dessen., A. Quemard., J.S. Blanchard., W.R. Jacobs., J.C. Sacchettini Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis Science 267 1995 1638-1641.
96. D.A. Rozwarski., G.A. Grant., D.H.R. Barton., W.R. Jacobs., J.C. Sacchettini Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis Science 279 1998 98-102.
97. J. Poehlsgaard., S. Douthwaite The bacterial ribosome as a target for antibiotics Nat Rev Microbiol 3 2005 870-881.
98. J.C. Wang Untangling the Double Helix: DNA Entanglement and the Action of the DNA Topoisomerases 2009 Cold Spring Harbour Laboratory Press Cold Spring Harbor, NY.
99. R.J. Reece., A. Maxwell DNA Gyrase: structure and function Crit Rev Biochem Mol Biol 26 1991 335-375.
100. B.D. Bax., P.F. Chan., D.E. Eggleston., A. Fosberry., D.R. Gentry., R. Gorrec., et al. Type IIA topoisomerase inhibition by a new class of antibacterial agents Nature 466 2010 935-942.
101. S. Bellon., J.D. Parsons., Y. Wei., K. Haakawa., L.L. Swenson., P.S. Charifson., et al. Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase Antimicrob Agents Chemother 48 2004 1856-1864.
102. V. Lamour., L. Hoermann., J.M. Jeltsch., P. Oudet., D. Moras An open conformation of the Thermus thermophilus gyrase B ATP-binding domain J Biol Chem 277 2002 18947-18953.
103. A.E. Eakin., O. Green., N. Hales., G.K. Walkup., S. Bist., A. Singh., et al. Pyrrolamide DNA gyrase inhibitors: fragment-based nuclear magnetic resonance screening to identify antibacterial agents Antimicrob Agents Chemother 56 2012 1240-1246.
104. L.W. Tari., M. Trzoss., D.C. Bensen., X. Li., Z. Chen., T. Lam., et al. Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity Bioorg Med Chem Lett 23 2013 1529-1536.
105. B.A. Sherer., K. Hull., O. Green., G. Basarab., S. Hauck., P. Hill., et al. Pyrrolamide DNA gyrase inhibitors: optimization of antibacterial activity and efficacy Bioorg Med Chem Lett 21 2011 7416-7420.
106. GS Basarab., PJ Hill., CE Garner., K Hull., O Green., BA Sherer., et al. Optimization of pyrrolamide topoisomerase II inhibitors towards identification of an antibacterial clinical candidate (AZD5099) J Med Chem 57 2014 6060-6082.